Rhabdomyosarcoma

Raphael L. Yechieli; Henry C. Mandeville; Susan M. Hiniker; Valerie Bernier-Chastagner; Susan McGovern; Giovanni Scarzello; Suzanne Wolden; Alison Cameron; John Breneman; Raquel Davila Fajardo; Sarah S. Donaldson

doi:10.1002/pbc.28254

Rhabdomyosarcoma

Raphael L. Yechieli, Henry C. Mandeville, Susan M. Hiniker, Valerie Bernier-Chastagner, Susan McGovern, Giovanni Scarzello, Suzanne Wolden, Alison Cameron, John Breneman, Raquel Davila Fajardo, Sarah S. Donaldson

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with a metastatic disease. We reviewed and contrasted the North American and European practice patterns, though ultimately the principles of staging, surgery, radiation therapy, and chemotherapy are similar in both Children's Oncology Group and International Society of Paediatric Oncology treatment approaches. Efforts are underway to investigate improved local control rates in higher risk patients using radiation dose escalation strategies, and delayed primary excision in select cases. The prognostic significance of imaging-based chemotherapy response, proton therapy, novel biomarkers, and targeted drugs will be determined in upcoming clinical trials.

Original language	English
Article number	e28254
Journal	Pediatric Blood and Cancer
Volume	68
Issue number	S2
DOIs	https://doi.org/10.1002/pbc.28254
Publication status	Published - May 2021
Externally published	Yes

Keywords

chemotherapy
Rhabdomyosarcoma
surgery radiation oncology

Access to Document

10.1002/pbc.28254

Cite this

@article{4cf4cfc8bd7a451bb1077efaafb6bb4d,

title = "Rhabdomyosarcoma",

abstract = "Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with a metastatic disease. We reviewed and contrasted the North American and European practice patterns, though ultimately the principles of staging, surgery, radiation therapy, and chemotherapy are similar in both Children's Oncology Group and International Society of Paediatric Oncology treatment approaches. Efforts are underway to investigate improved local control rates in higher risk patients using radiation dose escalation strategies, and delayed primary excision in select cases. The prognostic significance of imaging-based chemotherapy response, proton therapy, novel biomarkers, and targeted drugs will be determined in upcoming clinical trials.",

keywords = "chemotherapy, Rhabdomyosarcoma, surgery radiation oncology",

author = "Yechieli, {Raphael L.} and Mandeville, {Henry C.} and Hiniker, {Susan M.} and Valerie Bernier-Chastagner and Susan McGovern and Giovanni Scarzello and Suzanne Wolden and Alison Cameron and John Breneman and Fajardo, {Raquel Davila} and Donaldson, {Sarah S.}",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",

year = "2021",

month = may,

doi = "10.1002/pbc.28254",

language = "English",

volume = "68",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "S2",

}

TY - JOUR

T1 - Rhabdomyosarcoma

AU - Yechieli, Raphael L.

AU - Mandeville, Henry C.

AU - Hiniker, Susan M.

AU - Bernier-Chastagner, Valerie

AU - McGovern, Susan

AU - Scarzello, Giovanni

AU - Wolden, Suzanne

AU - Cameron, Alison

AU - Breneman, John

AU - Fajardo, Raquel Davila

AU - Donaldson, Sarah S.

PY - 2021/5

Y1 - 2021/5

N2 - Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with a metastatic disease. We reviewed and contrasted the North American and European practice patterns, though ultimately the principles of staging, surgery, radiation therapy, and chemotherapy are similar in both Children's Oncology Group and International Society of Paediatric Oncology treatment approaches. Efforts are underway to investigate improved local control rates in higher risk patients using radiation dose escalation strategies, and delayed primary excision in select cases. The prognostic significance of imaging-based chemotherapy response, proton therapy, novel biomarkers, and targeted drugs will be determined in upcoming clinical trials.

AB - Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with a metastatic disease. We reviewed and contrasted the North American and European practice patterns, though ultimately the principles of staging, surgery, radiation therapy, and chemotherapy are similar in both Children's Oncology Group and International Society of Paediatric Oncology treatment approaches. Efforts are underway to investigate improved local control rates in higher risk patients using radiation dose escalation strategies, and delayed primary excision in select cases. The prognostic significance of imaging-based chemotherapy response, proton therapy, novel biomarkers, and targeted drugs will be determined in upcoming clinical trials.

KW - chemotherapy

KW - Rhabdomyosarcoma

KW - surgery radiation oncology

UR - http://www.scopus.com/inward/record.url?scp=85103667846&partnerID=8YFLogxK

U2 - 10.1002/pbc.28254

DO - 10.1002/pbc.28254

M3 - Article

C2 - 33818882

AN - SCOPUS:85103667846

SN - 1545-5009

VL - 68

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - S2

M1 - e28254

ER -

Rhabdomyosarcoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this